UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies

Drug resistance updates, 2012-02, Vol.15 (1), p.50-61

2012

Volltextzugriff (PDF)

BCL-XL directly modulates RAS signalling to favour cancer cell stemness

Nature communications, 2017-10, Vol.8 (1), p.1-11, Article 1123

2017

Volltextzugriff (PDF)

BCL-X L directly modulates RAS signalling to favour cancer cell stemness

Nature communications, 2017-10, Vol.8 (1), p.1123

2017

Volltextzugriff (PDF)

Targeting of MCL-1 in breast cancer-associated fibroblasts reverses their myofibroblastic phenotype and pro-invasive properties

Cell death & disease, 2022-09, Vol.13 (9), p.787-787, Article 787

2022

Volltextzugriff (PDF)

Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype

Breast cancer (Tokyo, Japan), 2024-09, Vol.31 (5), p.825-840

2024

Volltextzugriff (PDF)

Histone Deacetylase Inhibitors Influence Chemotherapy Transport by Modulating Expression and Trafficking of a Common Polymorphic Variant of the ABCG2 Efflux Transporter

Cancer research (Chicago, Ill.), 2012-07, Vol.72 (14), p.3642-3651

2012

Volltextzugriff (PDF)

Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells

Molecular cancer, 2011-07, Vol.10 (1), p.80-80, Article 80

2011

Volltextzugriff (PDF)

Pancreatic cancer: Targeting KRAS and the vitamin D receptor via microtubules

Nature reviews. Clinical oncology, 2015-08, Vol.12 (8), p.442-444

2015

Volltextzugriff (PDF)

Targeting KRAS and the vitamin D receptor via microtubules

Nature reviews. Clinical oncology, 2015-08, Vol.12 (8), p.442-444

2015

Volltextzugriff (PDF)

Histone Deacetylase Inhibitors: Emerging Mechanisms of Resistance

Molecular pharmaceutics, 2011-12, Vol.8 (6), p.2021-2031

2011

Volltextzugriff (PDF)

R-Loop-Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin

Molecular cancer research, 2021-08, Vol.19 (8), p.1361-1374

2021

Volltextzugriff (PDF)

Antitumor effect of pharmacologic ascorbate in the B16 murine melanoma model

Free radical biology & medicine, 2015-10, Vol.87, p.193-203

2015

Volltextzugriff (PDF)

Brain Neural Progenitors are New Predictive Biomarkers for Breast Cancer Hormonotherapy

Cancer research communications, 2022-08, Vol.2 (8), p.857-869

2022

Volltextzugriff (PDF)

Abstract 1771: Metabolic reprogramming in KRAS mutant cancer cells may cause sensitivity to the histone deacetylase (HDAC) inhibitor romidepsin

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.1771-1771

2015

Volltextzugriff (PDF)

A Histone Deacetylase Inhibitor Induces Acetyl-CoA Depletion Leading to Lethal Metabolic Stress in RAS-Pathway Activated Cells

Cancers, 2022-05, Vol.14 (11), p.2643

2022

Volltextzugriff (PDF)

Abstract LB_C03: Protein translation inhibition enforces histone deacetylase inhibitor activity resulting in synergistic pancreatic cancer cell death

Molecular cancer therapeutics, 2023-12, Vol.22 (12_Supplement), p.LB_C03-LB_C03

2023

Volltextzugriff (PDF)

Abstract 2193: Characterization of the aggresome targeted Q141K ABCG2/BCRP variant

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.2193-2193

2013

Volltextzugriff (PDF)

Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras

Oncotarget, 2016-10, Vol.7 (43), p.69804-69815

2016

Volltextzugriff (PDF)

Abstract 5536: Short-term romidepsin treatment combined with MAPK pathway inhibition results in decreased mitochondrial hexokinase 2, increased mitochondrial Bim and apoptosis in BRAF mutant cancers

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.5536-5536

2014

Volltextzugriff (PDF)

Abstract 2610: Histone deacetylase inhibitors mediate pharmacological rescue of the ABCG2 Q141K variant: Potential for therapeutics in cancer and gout

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.2610-2610

2011

Volltextzugriff (PDF)

Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration

Cancer biology & therapy, 2013-02, Vol.14 (2), p.175-183

2013

Volltextzugriff (PDF)

Intérêt de l’outil web bc-GenExMiner en oncologie

Bulletin du cancer, 2021-11, Vol.108 (11), p.1057-1064

2021

Volltextzugriff (PDF)

Gout, genetics and ABC transporters

F1000 biology reports, 2011-11, Vol.3, p.23-23

2011

Volltextzugriff (PDF)

ABCG2, THE BREAST CANCER RESISTANCE PROTEIN (BCRP)

Drug Transporters, 2022, p.235-256

2022

Volltextzugriff (PDF)

The ABCG2 Multidrug Transporter

ABC Transporters - 40 Years On, 2015, p.195-226

2015

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(23)
Buchkapitel
(4)

Sprache

Englisch
(26)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(15)
Life Sciences & Biomedicine
(14)
Humans
(12)
Oncology
(9)
Breast Cancer
(5)
Cell Line, Tumor
(5)
Female
(5)
Histone Deacetylase Inhibitors - Pharmacology
(5)
Apoptosis
(4)
Cancer
(4)
Life Sciences
(4)
Romidepsin
(4)
Tumors
(4)
Animals
(3)
Breast Neoplasms - Metabolism
(3)
Cell Biology
(3)
Genetic Aspects
(3)
Mice
(3)
Pancreatic Cancer
(3)
Pharmacology & Pharmacy
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies

BCL-XL directly modulates RAS signalling to favour cancer cell stemness

BCL-X L directly modulates RAS signalling to favour cancer cell stemness

Targeting of MCL-1 in breast cancer-associated fibroblasts reverses their myofibroblastic phenotype and pro-invasive properties

Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype

Histone Deacetylase Inhibitors Influence Chemotherapy Transport by Modulating Expression and Trafficking of a Common Polymorphic Variant of the ABCG2 Efflux Transporter

Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells

Pancreatic cancer: Targeting KRAS and the vitamin D receptor via microtubules

Targeting KRAS and the vitamin D receptor via microtubules

Histone Deacetylase Inhibitors: Emerging Mechanisms of Resistance

R-Loop-Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin

Antitumor effect of pharmacologic ascorbate in the B16 murine melanoma model

Brain Neural Progenitors are New Predictive Biomarkers for Breast Cancer Hormonotherapy

Abstract 1771: Metabolic reprogramming in KRAS mutant cancer cells may cause sensitivity to the histone deacetylase (HDAC) inhibitor romidepsin

A Histone Deacetylase Inhibitor Induces Acetyl-CoA Depletion Leading to Lethal Metabolic Stress in RAS-Pathway Activated Cells

Abstract LB_C03: Protein translation inhibition enforces histone deacetylase inhibitor activity resulting in synergistic pancreatic cancer cell death

Abstract 2193: Characterization of the aggresome targeted Q141K ABCG2/BCRP variant

Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras

Abstract 5536: Short-term romidepsin treatment combined with MAPK pathway inhibition results in decreased mitochondrial hexokinase 2, increased mitochondrial Bim and apoptosis in BRAF mutant cancers

Abstract 2610: Histone deacetylase inhibitors mediate pharmacological rescue of the ABCG2 Q141K variant: Potential for therapeutics in cancer and gout

Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration

Intérêt de l’outil web bc-GenExMiner en oncologie

Gout, genetics and ABC transporters

ABCG2, THE BREAST CANCER RESISTANCE PROTEIN (BCRP)

The ABCG2 Multidrug Transporter

Suchergebnisse filtern